NGNE:NASDAQ
Neurogene Inc
$28.01
arrow_downward
-2.78%(-0.80) 1D
Jun 10, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NGNE...
Open
$28.90
High
$29.08
Low
$27.04
Mkt. cap
442.61M
Avg. vol.
146.42K
Volume
0.00
52-wk high
$37.27
52-wk low
$14.65
EPS
-$4.54
Beta
1.69
Shares outstanding
15.80M
No. of employees
131
Open
$28.90
High
$29.08
Low
$27.04
Mkt. cap
442.61M
Avg. vol.
146.42K
Volume
0.00
52-wk high
$37.27
52-wk low
$14.65
EPS
-$4.54
Beta
1.69
Shares outstanding
15.80M
No. of employees
131
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to NGNE in the past 3 months
Strong Buy
Buy
9
Hold
0
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for NGNE in the last 3 months.
Highest
Current $28.01
$180.00 (+542.63%)
Average
$80.00 (+185.61%)
Lowest
$46.00 (+64.23%)
News stories
From sources across the web
Investing.com
·
1 day ago
Neurogene stock rating reiterated at Buy by H.C. Wainwright
GuruFocus
·
2 days ago
Neurogene (NGNE) Completes Dosing in Key Trial for NGN-401
TipRanks
·
2 days ago
Neurogene Completes Dosing in Embolden Rett Trial
Stock Titan
·
2 days ago
25 girls receive Neurogene’s one-time gene therapy in key Rett syndrome trial
About Neurogene Inc
CEOJonathan Drachman M.D.
Employees131
Founded2018
Headquarters-
SectorBiotechnology
Websiteneurogene.com
AI content may include mistakes. Learn more